About this trial
This study looks at whether using Avutometinib (VS-6766) together with Defactinib can be an effective treatment for advanced or recurrent mesonephric gynecologic cancer. The goal is to see how well these medicines work when given to patients with this type of cancer.
The trial's ID number is NCT05787561. This is a Phase 2 study, which means it is looking at how well the treatments work and how safe they are. The trial is FDA-regulated and aims to include about 40 participants.
Who can join
Women aged 18 and older can join this study. They must have a confirmed diagnosis of mesonephric gynecologic cancer and have measurable disease. Patients with ongoing or returning cancer after previous treatments can participate. The trial team will check to make sure everyone meets the eligibility requirements.
Condition
Mesonephric Gynecologic Cancer
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
All participants will receive the combination treatment of Avutometinib (VS-6766) and Defactinib. They will take Avutometinib twice a week and Defactinib twice a day for three weeks, followed by a one-week break. This cycle will repeat every four weeks.
Where
This trial is running at 7 locations in the United States. All of them are currently recruiting.
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey
Memorial Sloan Kettering Cancer Center
New York, New York
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York
Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities)
Commack, New York
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York